PRESS DIGEST- Financial Times - November 7

Reuters
Nov 07, 2025
PRESS DIGEST- Financial Times - November 7

Nov 7 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Headlines

- Novo Nordisk challenges Pfizer to raise offer for obesity biotech

- Comcast holds talks about buying ITV's television business

- Messina Group seeks to sell stake in lobbying firm co-founded by Peter Mandelson

- Reeves considers less dramatic cut to cash Isa allowance

Overview

- Novo Nordisk's NOVOb.CO chief executive challenged Pfizer PFE.N to increase its bid for obesity start-up Metsera MTSR.O, as the Denmark-based drugmaker again bested its U.S. rival's offer for the biotech.

- Comcast CMCSA.O is in talks with ITV ITV.L about buying its television business, in a deal that could result in it being combined with the U.S. media giant's Sky subsidiary to create a leading broadcast and streaming group in the UK.

- The Messina Group, the U.S. political consulting firm run by a former aide of Barack Obama, is seeking to sell off its stake in Global Counsel, the lobbying outfit co-founded by Lord Peter Mandelson.

- British Finance Minister Rachel Reeves is considering a less dramatic cut to the annual cash Isa allowance following a backlash from building societies, as the chancellor tries to push through potentially unpopular reforms to funnel more money into UK stocks.

(Compiled by Bengaluru newsroom)

((globalnewsmonitoring@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10